Aurobindo Pharma Reports 2% Increase in Q4 Profit, Driven by Growth in Europe and Emerging Markets

Aurobindo Pharma Reports Modest 2 Percent Rise in Q4FY26 Net Profit

Aurobindo Pharma, a leading pharmaceutical company, reported a modest 2 percent year-on-year rise in Q4FY26 net profit, as strong growth in Europe and other markets helped offset weakness in the US business. The company's net profit stood at Rs.921 crore for the March quarter, with revenue rising 5.6 percent to Rs.8,853 crore.

The company's EBITDA grew a marginal 0.5 percent to Rs.1,801 crore, while EBITDA margins fell to 20.3 percent from 21.4 percent a year earlier. The decline in EBITDA margins reflects margin compression and higher overheads, even as strong geographical diversification supported revenues.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Segmentally, the performance was mixed. The US formulations business declined 13 percent YoY to Rs.3,543 crore, impacted by lower sales. In contrast, Europe revenues surged 30.2 percent to Rs.2,795 crore, emerging as the key growth driver, while growth markets rose 24.7 percent to Rs.980 crore. The antiretroviral (ARV) or anti-HIV drugs segment grew 6.4 percent to Rs.328 crore, and the active pharmaceutical ingredient (API) business increased 12.9 percent to Rs.1,208 crore, supported by volume expansion.

For the full year, Aurobindo reported revenue of Rs.33,653 crore, up 6.1 percent YoY, while EBITDA rose 3.8 percent to Rs.6,856 crore with margins easing to 20.4 percent from 20.8 percent. Net profit increased just 0.6 percent to Rs.3,503 crore, reflecting pressure on profitability.

The subdued earnings growth was driven by weaker US performance, higher operating costs and some forex-related impact, partially offset by lower finance costs and stable gross margins. Operationally, the company continued to expand its pipeline, receiving nine ANDA approvals and launching 12 products during the quarter. Europe also crossed a key milestone, generating over €1 billion in FY26 revenues, highlighting a structural shift in growth drivers.

Aurobindo ended the year with a strong net cash position of about $317 million, supported by steady cash flows even after capex and acquisitions. Looking ahead, the company said it is focusing on scaling biosimilars, specialty products and new launches, alongside investments in manufacturing capacity to support long-term growth.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline